{"id":64501,"date":"2024-09-28T12:04:52","date_gmt":"2024-09-28T12:04:52","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=64501"},"modified":"2026-04-30T10:23:29","modified_gmt":"2026-04-30T10:23:29","slug":"bupcart-xl-150","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/bupcart-xl-150\/","title":{"rendered":"Bupcart-XL 150"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u0391\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Bupcart-XL 150 (Bupropion 150 mg, extended-release (XL)) is a dopamine-noradrenaline reuptake inhibitor (NDRI) used for major depression, smoking cessation (Zyban indication), and seasonal affective disorder. Distinct profile: stimulating rather than sedating, weight-neutral or weight-reducing, no sexual side effects. XL is once-daily \u2014 better adherence than the BID SR formulation.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Bupcart-XL 150 at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> \u2014 \u03c0\u03b1\u03c1\u03ac\u03b8\u03c5\u03c1\u03bf \u03ac\u03c6\u03b9\u03be\u03b7\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03ae \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7 \u2014 \u03ba\u03b1\u03b9 \u03b4\u03b9\u03ba\u03b1\u03b9\u03bf\u03cd\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03c6\u03bf\u03c3\u03af\u03c9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. \u0394\u03b9\u03b1\u03c4\u03af\u03b8\u03b5\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03c1\u03bf\u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2.<\/p>\n

What Bupcart-XL 150 is and how it works<\/h2>\n

Bupcart-XL 150 is a 150 mg bupropion extended-release (XL) tablet supplied by Cardinal Healthcare. Bupropion is the only widely-prescribed antidepressant whose primary action is dopamine-noradrenaline reuptake inhibition \u2014 not serotonin reuptake. This makes it pharmacologically distinct from SSRIs\/SNRIs\/TCAs and explains its different side-effect signature.<\/p>\n

The clinical translation: bupropion does not cause sexual dysfunction, does not cause weight gain (often weight loss), and is activating rather than sedating. The trade-off is a meaningful increase in seizure risk at high doses, an absolute contraindication in eating disorders, and an insomnia\/anxiety burden in some patients.<\/p>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0395\u03ba\u03ba\u03af\u03bd\u03b7\u03c3\u03b7<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n\u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf<\/th>\n<\/tr>\n<\/thead>\n
Major depression \u2014 XL<\/td>\n150 mg OD morning<\/td>\n300 mg OD<\/td>\n450 mg<\/td>\n<\/tr>\n
Major depression \u2014 SR<\/td>\n150 mg OD \u00d7 3 d \u2192 BID<\/td>\n150 mg BID<\/td>\n200 mg BID<\/td>\n<\/tr>\n
Smoking cessation<\/td>\n150 mg OD \u00d7 3 d \u2192 BID (SR) or 150 mg OD \u00d7 1 wk \u2192 300 mg (XL)<\/td>\n150 mg BID or 300 mg OD \u00d7 7\u201312 weeks<\/td>\n\u2014<\/td>\n<\/tr>\n
Seasonal affective disorder (XL)<\/td>\n150 mg OD autumn start<\/td>\n300 mg OD<\/td>\n\u2014<\/td>\n<\/tr>\n
SSRI sexual dysfunction (off-label)<\/td>\n75\u2013150 mg OD<\/td>\n150 mg OD<\/td>\n300 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\nSeizure risk \u2014 absolute and dose-dependent<\/strong><\/p>\n

Bupropion lowers seizure threshold. Absolute contraindications:<\/strong> any seizure disorder, current or historical anorexia nervosa or bulimia, abrupt withdrawal from alcohol or sedatives. The seizure risk at 300 mg\/day is approximately 0.1%; at 450 mg\/day it is approximately 0.4% \u2014 a 4-fold rise. Single doses must not exceed 150 mg (SR) or 450 mg total (XL).<\/p>\n<\/div>\n

\nEating-disorder contraindication<\/strong><\/p>\n

Anorexia and bulimia are absolute contraindications \u2014 both because eating-disorder physiology lowers seizure threshold (electrolyte derangement, ketotic state) and because bupropion’s appetite-suppressant effect can entrench restrictive behaviour. This is one of the few clear “do not use” boxes in psychiatry.<\/p>\n<\/div>\n

\nMAOI washout<\/strong><\/p>\n

14-day washout each direction. Concurrent use risks hypertensive crisis.<\/p>\n<\/div>\n

\n\u039c\u03b1\u03cd\u03c1\u03bf \u03c0\u03bb\u03b1\u03af\u03c3\u03b9\u03bf \u03b1\u03c5\u03c4\u03bf\u03ba\u03c4\u03bf\u03bd\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 (\u03ba\u03ac\u03c4\u03c9 \u03c4\u03c9\u03bd 25)<\/strong><\/p>\n

\u038c\u03bb\u03b1 \u03c4\u03b1 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03c4\u03b1\u03b8\u03bb\u03b9\u03c0\u03c4\u03b9\u03ba\u03ac \u03c6\u03ad\u03c1\u03bf\u03c5\u03bd \u03c0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03bc\u03b1\u03cd\u03c1\u03bf\u03c5 \u03c0\u03bb\u03b1\u03b9\u03c3\u03af\u03bf\u03c5 \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd FDA \u03b3\u03b9\u03b1 \u03b1\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03b7 \u03b1\u03c5\u03c4\u03bf\u03ba\u03c4\u03bf\u03bd\u03b9\u03ba\u03ae \u03b9\u03b4\u03ad\u03b1 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03ba\u03ac\u03c4\u03c9 \u03c4\u03c9\u03bd 25 \u03b5\u03c4\u03ce\u03bd.<\/p>\n<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n